Thyroid tumors: Novel insights from proteomic studies

Expert Review of Proteomics

Volumn 6, Issue 4, 2009, Pages 363-376

  Damante, Giuseppe ^a   Scaloni, Andrea ^b   Tell, Gianluca ^a  

^a Dipartimento di Scienze e Tecnologie Biomediche   (Italy)

^b CNR   (Italy)

Author keywords

Biomarker discovery; Differential proteomics; Fine needle aspiration biopsy; Thyroid cancer; Thyroid cell

Indexed keywords

BIOLOGICAL MARKER;

GENE EXPRESSION PROFILING; GENOMICS; HUMAN; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; REVIEW; THYROID FOLLICLE CELL; THYROID TUMOR; TREATMENT OUTCOME; TUMOR DIAGNOSIS;

ANIMALS; HUMANS; PROTEOMICS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 69549087932     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.09.51     Document Type: Review

References (130)

1. Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. Br. J. Cancer 85(9), 1335-1339 (2001).
2. Farahati J, Geling M, Mäder U et al. Changing trends of incidence and prognosis of thyroid carcinoma in lower Franconia, Germany, from 1981-1995. Thyroid 14(2), 141-147 (2004).
3. Eszlinger M, Krohn K, Hauptmann S, Dralle H, Giordano TJ, Paschke R. Perspectives for improved and more accurate classification of thyroid epithelial tumors. J. Clin. Endocrinol. Metab. 93(9), 3286-3294 (2008). • Classification of thyroid cancer by integrating molecular features and histology.
4. Gimm O. Thyroid Cancer. Cancer Lett. 163(2), 143-156 (2001).
5. Potenza M, Mechanick Ji. Low-risk thyroid carcinoma: when is the treatment worse than the disease? Expert Rev. Endocrinol. Metab. 4(1), 5-7 (2009).
6. Melillo RM, Castellone MD, Guarino V et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 115(4), 1068-1081 (2005). (Pubitemid 40489412)
7. Hunt J. Understanding the genotype of follicular thyroid tumors. Endocr. Pathol. 16(4), 311-321 (2005). (Pubitemid 43787107)
8. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J. Clin. Endocrinol. Metab. 83(11), 4116-4122 (1998). (Pubitemid 28513605)
9. Basolo F, Giannini R, Monaco C et al. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am. J. Pathol. 160(1), 247-754 (2002). (Pubitemid 34052285)
10. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J. Clin. Endocrinol. Metab. 88(6), 2745-2752 (2003). (Pubitemid 36724451)
11. Castro P, Rebocho AP, Soares RJ et al. PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 91(1), 213-220 (2006). (Pubitemid 43069140)
12. Nikiforova MN, Kimura ET, Gandhi M et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88(11), 5399-5404 (2003). (Pubitemid 37452745)
13. Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod. Pathol. 17(11), 1359-1363 (2004). (Pubitemid 39472990)
14. Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103(11), 2261-2268 (2005). (Pubitemid 40686569)
15. Damante G, Tell G, Di Lauro R. A unique combination of transcription factors controls differentiation of thyroid cells. Prog. Nucleic Acid Res. Mol. Biol. 66, 307-356 (2001).
16. Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res. 54(17), 4744-4749 (1994). (Pubitemid 24276506)
17. Ros P, Rossi DL, Acebrón A, Santisteban P. Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis. Biochimie 81(4), 389-396 (1999).
18. Vasko V, Espinosa AV, Scouten W et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc. Natl. Acad. Sci. USA 104(8), 2803-2808 (2007). (Pubitemid 46327960)
19. Guarino V, Faviana P, Salvatore G et al. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J. Clin. Endocrinol. Metab. 90(9), 5270-5278 (2005). (Pubitemid 41262285)
20. Fluge Ø, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 16(2), 161-175 (2006).
21. Puppin C, Fabbro D, Dima M et al. High periostin expression correlates with aggressiveness in papillary thyroid carcinomas. J. Endocrinol. 197(2), 401-408 (2008). (Pubitemid 351696253)
22. Barden CB, Shister KW, Zhu B et al. Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin. Cancer Res. 9(5), 1792 - 1800 (2003).
23. Finley DJ, Zhu B, Barden CB, Fahey TJ. Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann. Surg. 240(3), 425-436 (2004). (Pubitemid 39121337)
24. Mazzanti C, Zeiger MA, Costouros NG et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 64(8), 2898-2903 (2004). (Pubitemid 38500631)
25. Weber F, Shen L, Aldred MA et al. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J. Clin. Endocrinol. Metab. 90(5), 2512-2521 (2005). (Pubitemid 40686285)
26. Fontaine JF, Mirebeau-Prunier D, Franc B et al. Microarray analysis refines classification of non-medullary thyroid tumours of uncertain malignancy. Oncogene 27(15), 2228-2236 (2008).
27. Jarzab B, Wiench M, Fujarewicz K et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 65(4), 1587-1597 (2005). (Pubitemid 40270189)
28. Kebebew E, Peng M, Reiff E, McMillan A. Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer 106(12), 2592-2597 (2006). (Pubitemid 43911825)
29. Tian Q, Stepaniants SB, Mao M et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol. Cell. Proteomics 3(10), 960-969 (2004). (Pubitemid 40361231)
30. Hanash S. Disease proteomics. Nature 422(6928), 226-232 (2003).
31. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 422(6928), 198-207 (2003).
32. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 563(1), 23-60 (2005).
33. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 452(7187), 571-579 (2008).
34. O'Farrell PH. High resolution twodimensional electrophoresis of proteins. J. Biol. Chem. 250(10), 4007-4021 (1975).
35. Bjellqvist B, Ek K, Righetti PG et al. Isoelectric focusing in immobilized pH gradients: principle, methodology and some applications. J. Biochem. Biophys. Methods 6(4), 317-339 (1982).
36. Yates JR, Gilchrist A, Howell KE, Bergeron JJ. Proteomics of organelles and large cellular structures. Nat. Rev. Mol. Cell. Biol. 6(9), 702-714 (2005). (Pubitemid 41742794)
37. Everley PA, Zetter BR. Proteomics in tumor progression and metastasis. Ann. NY Acad. Sci. 1059, 1-10 (2005).
38. Cho WC. Contribution of oncoproteomics to cancer biomarker discovery. Mol. Cancer 6, 25-38 (2007).
39. Verrills NM. Clinical proteomics: present and future prospects. Clin. Biochem. Rev. 27(2), 99-116 (2006).
40. Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 4(12), 3665-3685(2004). (Pubitemid 39657447)
41. Timms JF, Cramer R. Difference gel electrophoresis. Proteomics 8(23-24), 4886-4897 (2008).
42. Riederer BM. Non-covalent and covalent protein labeling in two-dimensional gel electrophoresis. J. Proteomics 71(2), 231-244 (2008).
43. Seike M, Kondo T, Fujii K et al. Proteomic signatures for histological types of lung cancer. Proteomics 5(11), 2939-2948 (2005). (Pubitemid 41059770)
44. Friedman DB, Hill S, Keller JW et al. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 4(3), 793-811 (2004). (Pubitemid 38339157)
45. Sun W, Xing B, Sun Y et al. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol. Cell. Proteomics 6(10), 1798 - 1808 (2007).
46. Somiari RI, Sullivan A, Russell S et al. High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics 3(10), 1863-1873 (2003).
47. Zhou G, Li H, DeCamp D et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol. Cell. Proteomics 1(2), 117-124 (2002).
48. Morita A, Miyagi E, Yasumitsu H, Kawasaki H, Hirano H, Hirahara F. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Proteomics 6(21), 5880-5890 (2006). (Pubitemid 44764024)
49. Gharbi S, Gaffney P, Yang A et al. Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol. Cell. Proteomics 1(2), 91-98 (2002).
50. Han X, Aslanian A, Yates JR. Mass spectrometry for proteomics. Curr. Opin. Chem. Biol. 12(5), 483-490 (2008).
51. Lim MS, Elenitoba-Johnson KS. Proteomics in pathology research. Lab. Invest. 84(10), 1227-1244 (2004).
52. Palagi PM, Hernandez P, Walther D, Appel RD. Proteome informatics I: bioinformatics tools for processing experimental data. Proteomics 6(20), 5435-5444 (2006). (Pubitemid 44683213)
53. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat. Biotechnol. 21(3), 255-261 (2003).
54. Ong SE, Mann M. Mass spectrometrybased proteomics turns quantitative. Nat. Chem. Biol. 1(5), 252-262 (2005).
55. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17(10), 994-999 (1999). (Pubitemid 29474856)
56. Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using aminereactive isobaric tagging reagents. Mol. Cell. Proteomics 3(12), 1154-1169 (2004).
57. Ong SE, Blagoev B, Kratchmarova I et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1(5), 376-386 (2002).
58. Washburn MP, Wolters D, Yates JR. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19(3), 242-247 (2001). (Pubitemid 32220565)
59. Swanson SK, Florens L, Washburn MP. Generation and analysis of multidimensional protein identification technology datasets. Methods Mol. Biol. 492, 1-20 (2009).
60. Hall DA, Ptacek J, Snyder M. Protein microarray technology. Mech. Ageing Dev. 128(1), 161-167 (2007).
61. Tang N, Tornatore P, Weinberger SR. Current developments in SELDI affinity technology. Mass Spectrom. Rev. 23(1), 34-44 (2004).
62. Xiao Z, Adam BL, Cazares LH et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 61(16), 6029-6033 (2001). (Pubitemid 32762533)
63. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577 (2002).
64. Villanueva J, Shaffer DR, Philip J et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116(1), 271-284 (2006). (Pubitemid 43121812)
65. Weinberger SR, Dalmasso EA, Fung ET. Current achievements using ProteinChip Array technology. Curr. Opin. Chem. Biol. 6(1), 86-91 (2002).
66. Caiazzo RJ, Maher AJ, Drummond MP et al. Protein microarrays as an application for disease biomarkers. Proteomics Clin. Appl. 2, 138-147 (2009).
67. Phizicky E, Bastiaens PI, Zhu H, Snyder M, Fields S. Protein analysis on a proteomic scale. Nature 422(6928), 208-215 (2003).
68. Liotta LA, Espina V, Mehta AI et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3(4), 317-325 (2003). (Pubitemid 38340301)
69. Kodadek T. Protein microarrays: prospects and problems. Chem. Biol. 8(2), 105-115 (2001).
70. Greenbaum D, Baruch A, Hayrapetian L et al. Chemical approaches for functionally probing the proteome. Mol. Cell. Proteomics 1(1), 60-68 (2002).
71. Wilson DS, Nock S. Recent developments in protein microarray technology. Angew. Chem. Int. Ed. Engl. 42(5), 494-500 (2003). (Pubitemid 36232244)
72. Seeley EH, Caprioli RM. Molecular imaging of proteins in tissues by mass spectrometry. Proc. Natl. Acad. Sci. USA 105(47), 18126-18131 (2008).
73. Yanagisawa K, Shyr Y, Xu BJ et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362(9382), 433-439 (2003). (Pubitemid 36999706)
74. Schwartz SA, Weil RJ, Thompson RC et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res. 65(17), 7674-7681 (2005).
75. Xu BJ, Li J, Beauchamp RD et al. Identification of early intestinal neoplasia protein biomarkers using laser capture microdissection and MALDI MS. Mol. Cell. Proteomics 8(5), 936-945 (2009).
76. Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin. Chem. 53(5), 852-858 (2007). (Pubitemid 46744240)
77. Salzano AM, Paron I, Pines A et al. Differential proteomic analysis of nuclear extracts from thyroid cell lines. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 833(1), 41-50 (2006).
78. Paron I, Scaloni A, Pines A et al. Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem. Biophys. Res. Commun. 302(3), 545-553 (2003). (Pubitemid 36279565)
79. Paron I, D'Ambrosio C, Scaloni A et al. A differential proteomic approach to identify proteins associated with thyroid cell transformation. J. Mol. Endocrinol. 34(1), 199-207 (2005). (Pubitemid 40305560)
80. Marsee DK, Venkateswaran A, Tao H et al. Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells. J. Biol. Chem. 279(42), 43990-43997 (2004). •• HSP90 and its co-chaperone p50cdc37 associate with RET/PTC1. A specific HSP90 inhibitor reduces RET/PTC1 protein levels and may be useful as a chemotherapeutic agent. (Pubitemid 39390707)
81. Gorla L, Cantù M, Miccichè F et al. RET oncoproteins induce tyrosine phosphorylation changes of proteins involved in RNA metabolism. Cell Signal. 18(12), 2272-2282 (2006). (Pubitemid 44636167)
82. Gorla L, Mondellini P, Cuccuru G et al. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements. Mol. Carcinog. 48(3), 220-231 (2009).
83. Iannetti A, Pacifico F, Acquaviva R et al. The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc. Natl. Acad. Sci. USA 105(37), 14058-14063 (2008).
84. Pacifico F, Paolillo M, Chiappetta G et al. RbAp48 is a target of nuclear factor-kB activity in thyroid cancer. J. Clin. Endocrinol. Metab. 92(4), 1458-1466 (2007). • RbAp48, a protein participating in several chromatin-remodeling complexes, was identified as a NF-kB effector involved in thyroid cancer. (Pubitemid 46556426)
85. Ito T, Seyama T, Mizuno T et al. Unique association of p53 mutations with undifferentiated but not differentiated carcinomas of the thyroid gland. Cancer Res. 52(5), 1369-1371 (1992).
86. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pienotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest. 91(4), 1753-1760 (1993). (Pubitemid 23127381)
87. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. 91(1), 179-184 (1993). (Pubitemid 23037270)
88. Fusco A, Berlingieri MT, Di Fiore PP, Portella G, Grieco M, Vecchio G. Oneand two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol. Cell. Biol. 7(9), 3365-3370 (1987).
89. Friedlander P, Legros Y, Soussi T, Prives C. Regulation of mutant p53 temperature-sensitive DNA binding. J. Biol. Chem. 271(41), 25468-25478 (1996). (Pubitemid 26337921)
90. Casamassimi A, Miano MG, Porcellini A et al. p53 genes mutated in the DNA binding site or at a specific COOH-terminal site exert divergent effects on thyroid cell growth and differentiation. Cancer Res. 58(13), 2888-2894(1998). (Pubitemid 28311924)
91. Fiscella M, Zambrano N, Ullrich SJ et al. The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities. Oncogene 9(11), 3249-3257 (1994). (Pubitemid 24338453)
92. Keller DM, Lu H. p53 serine 392 phosphorylation increases after UV through induction of the assembly of the CK2.hSPT16.SSRP1 complex. J. Biol. Chem. 277(51), 50206-50213 (2002).
93. Pines A, Bivi N, Vascotto C et al. Nucleotide receptors stimulation by extracellular ATP controls Hsp90 expression through APE1/Ref-1 in thyroid cancer cells: a novel tumorigenic pathway. J. Cell. Physiol. 209(1), 44-55 (2006). (Pubitemid 44318666)
94. Pacifico F, Mauro C, Barone C et al. Oncogenic and anti-apoptotic activity of NF-κB in human thyroid carcinomas. J. Biol. Chem. 279(52), 54610-54619 (2004). (Pubitemid 40053204)
95. Qian YW, Wang YC, Hollingsworth Jr RE, Jones D, Ling N, Lee EY. A retinoblastomabinding protein related to a negative regulator of Ras in yeast. Nature 364(6438), 648-652 (1993). (Pubitemid 23274725)
96. Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13(15), 1924-1935 (1999).
97. Loyola A, Almouzni G. Histone chaperones, a supporting role in the limelight. Biochim. Biophys. Acta. 1677(1- 3), 3-11 (2004). (Pubitemid 38327083)
98. Russo D, Bisca A, Celano M et al. Proteomic analysis of human thyroid cell lines reveals reduced nuclear localization of Mn-SOD in poorly differentiated thyroid cancer cells. J. Endocrinol. Invest. 28(2), 137-144 (2005). (Pubitemid 43162789)
99. Obermaier C, Jankowski V, Schmutzler C et al. Free-flow isoelectric focusing of proteins remaining in cell fragments following sonication of thyroid carcinoma cells. Electrophoresis 26(11), 2109-2116 (2005). (Pubitemid 40852642)
100. Schweppe RE, Klopper JP, Korch C et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab. 93(11), 4331-4341 (2008). (Pubitemid 352789529)
101. Berger K, Wissmann D, Ihling C et al. Quantitative proteome analysis in benign thyroid nodular disease using the fluorescent ruthenium II tris(bathophenanthroline disulfonate) stain. Mol. Cell. Endocrinol. 227(1-2), 21-30 (2004). (Pubitemid 39389121)
102. Krause K, Schierhorn A, Sinz A et al. Toward the application of proteomics to human thyroid tissue. Thyroid 16(11), 1131-1143 (2006). (Pubitemid 44864488)
103. Lin JD, Huang CC, Weng HF, Chen SC, Jeng LB. Comparison of membrane proteins from benign and malignant human thyroid tissues by two-dimensional polyacrylamide gel electrophoresis. J. Chromatogr. B. Biomed. Appl. 667(1), 153-160 (1995).
104. Lin JD, Chan EC, Weng HF, Sheu CA. Two-dimensional electrophoretic analysis of membranous protein from human thyroid tissues and cancer cell lines. Electrophoresis 19(18), 3213-3216 (1998).
105. Krause K, Karger S, Schierhorn A, Poncin S, Many MC, Fuhrer D. Proteomic profiling of cold thyroid nodules. Endocrinology 148(4), 1754-1763 (2007). • Protein expression profiling of cold benign thyroid nodules revealed upregulation of three functional systems: thyroid cell proliferation, thyroglobulin turnover and H2O2 detoxification. (Pubitemid 46457138)
106. Brown LM, Helmke SM, Hunsucker SW et al. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol. Carcinog. 45(8), 613-626 (2006).
107. Giusti L, Iacconi P, Ciregia F et al. Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers. J. Proteome Res. 7(9), 4079-4088 (2008). •• Differential proteomics from FNAB samples revealed differences between PTCs, TCV and matched normal thyroid tissue.
108. Cortese F, Boffo V, Gargiani M, Servetti S, Argirò G, Casciani CU. Tall cell variant of papillary thyroid cancer. J. Exp. Clin. Cancer Res. 17(4), 3-52 (1998). (Pubitemid 29083430)
109. Samuni Y, Gamson J, Samuni A et al. Factors influencing nitroxide reduction and cytotoxicity in vitro. Antioxid. Redox Signal 6(3), 587-595 (2004). (Pubitemid 38625378)
110. Fujii J, Ikeda Y. Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep. 7(3), 3-10 (2002). (Pubitemid 34700435)
111. Pham CG, Bubici C, Zazzeroni F et al. Ferritin heavy chain upregulation by NF-κB inhibits TNFα-induced apoptosis by suppressing reactive oxygen species. Cell 119(4), 29-42 (2004). (Pubitemid 39482352)
112. Torres-Cabala C, Panizo-Santos A, Krutzsch HC et al. Differential expression of S100C in thyroid lesions. Int. J. Surg. Pathol. 12(2), 107-115 (2004). (Pubitemid 38542482)
113. Torres-Cabala C, Bibbo M, Panizo-Santos A et al. Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol. 50(5), 518-528 (2006). (Pubitemid 44449617)
114. Srisomsap C, Subhasitanont P, Otto A et al. Detection of cathepsin B upregulation in neoplastic thyroid tissues by proteomic analysis. Proteomics 2(6), 706-712 (2002). (Pubitemid 34693571)
115. Shuja S, Cai J, Iacobuzio-Donahue C et al. Cathepsin B activity and protein levels in thyroid carcinoma, Graves' disease, and multinodular goiters. Thyroid 9(6), 569-577 (1999). (Pubitemid 29296119)
116. Kusunoki T, Nishida S, Nakano T et al. Study on cathepsin B activity in human thyroid tumors. Auris Nasus Larynx 22(1), 43-48 (1995).
117. Franzoni A, Dima M, D'Agostino M et al. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. Thyroid 19(3), 247-255 (2009).
118. Netea-Maier RT, Hunsucker SW, Hoevenaars BM et al. Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res. 68(5), 1572-1580 (2008).
119. Suriano R, Lin Y, Ashok BT et al. Pilot study using SELDI-TOF-MS based proteomic profile for the identification of diagnostic biomarkers of thyroid proliferative diseases. J. Proteome Res. 5(4), 856-861 (2006).
120. Whelan LC, Power KA, McDowell DT, Kennedy J, Gallagher WM. Applications of SELDI-MS technology in oncology. J. Cell. Mol. Med. 12(5A), 1535-1547 (2008).
121. Wang JX, Yu JK, Wang L, Liu QL, Zhang J, Zheng S. Application of serum protein fingerprint in diagnosis of papillary thyroid carcinoma. Proteomics 6(19), 5344-5349 (2006). (Pubitemid 44547171)
122. Moretz WH, Gourin CG, Terris DJ et al. Detection of papillary thyroid carcinoma with serum protein profile analysis. Arch. Otolaryngol. Head Neck Surg. 134(2), 198-202 (2008).
123. Diamandis EP. Peptidomics for cancer diagnosis: present and future. J. Proteome Res. 5(9), 2079-2082 (2006).
124. Villanueva J, Martorella AJ, Lawlor K et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell. Proteomics 5(10), 1840-1852 (2006). •• A 12-member serum peptide signature was developed, which is able to distinguish healthy subjects from metastatic thyroid carcinoma patients with a 95% sensitivity and 95% specificity.
125. Villanueva J, Nazarian A, Lawlor K, Yi SS, Robbins RJ, Tempst P. A sequencespecific exopeptidase activity test (SSEAT) for 'functional' biomarker discovery. Mol. Cell. Proteomics 7(3), 509-518 (2008).
126. Linkov F, Ferris RL, Yurkovetsky Z et al. Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. Proteomics Clin. Appl. 2(12), 1575-1585 (2008).
127. Pang S, Smith J, Onley D et al. A comparability study of the emerging protein array platforms with established ELISA procedures. J. Immunol. Methods 302(1-2), 1-12 (2005). (Pubitemid 41111868)
128. Apel RL, Ezzat S, Bapat BV, Pan N, LiVolsi VA, Asa SL. Clonality of thyroid nodules in sporadic goiter. Diagn. Mol. Pathol. 4(2), 113-121 (1995).
129. Fusco A, Chiappetta G, Hui P et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am. J. Pathol. 160(6), 2157-2167 (2002). (Pubitemid 34663407)
130. Mustafa D, Kros JM, Luider T. Combining laser capture microdissection and proteomics techniques. Methods Mol. Biol. 428, 159-178 (2008).